线粒体呼吸链复合物Ⅰ缺陷导致幼儿肝内胆汁淤积症

线粒体呼吸链复合物缺陷是导致儿童线粒体病的主要原因。本文就1例线粒体呼吸链复合物Ⅰ缺陷导致的幼儿胆汁淤积症患者的临床经过、生化特点、线粒体呼吸链复合物活性分析及基因突变进行回顾性研究。患儿,男,自1岁1个月起腹泻,体重下降,伴无力、进行性黄疸、肝损害。经多种检查、尿液有机酸分析及血液氨基酸、酯酰肉碱谱分析未见特异性改变。外周血白细胞线粒体呼吸链复合物Ⅰ活性降低,线粒体基因分析发现患儿及其母亲tRNA 5821G>A突变,证实患儿存在线粒体呼吸链复合物Ⅰ缺陷。患儿疾病进展迅速,治疗无效,于1岁5个月时夭折。复合物Ⅰ缺陷是线粒体呼吸链缺陷中最常见的类型,本研究首次诊断了1例线粒体呼吸链复合物Ⅰ缺陷所导致的中国儿童患者,其临床表现为胆汁淤积症。线粒体肝病是导致儿童代谢性肝病的主要原因之一,生化分析、线粒体呼吸链复合物活性测定及基因分析是病因诊断的关键。     

线粒体呼吸链酶复合物V缺陷与线粒体病

线粒体呼吸链酶复合物V,也称为ATP合酶,是位于线粒体内膜上的大蛋白复合体,由2个功能性蛋白复合物F0及F1构成。复合物V是线粒体呼吸链的最后一个复合物,在线粒体中通过电化学梯度传递质子,以ADP、Pi及Mg2+为原料合成ATP,为细胞供能。大多数患者新生儿期发病,导致严重脑损害或多脏器损害,病死率很高。主要临床表现为神经肌肉病、心肌病、高乳酸血症及3 甲基戊烯二酸尿症等,因受累器官的不同导致显著的临床异质性。复合物V由16个亚基组成,由线粒体基因与核基因共同编码。迄今,国内外已报道了MT-ATP6、MT-ATP8、ATPAF2、TMEM70、ATP5E基因突变导致的复合物V缺陷。本文总结了线粒体呼吸链复合物V的结构及功能,并对复合物V缺陷的病理、临床表现、诊断、治疗及分子遗传学研究进展进行了综述。     

Intractable secretory diarrhea in a Japanese boy with mitochondrial respiratory chain complex I deficiency

The etiology of secretory diarrhea in early life is often unclear. We report a Japanese boy who survived until 3 years of age, despite intractable diarrhea commencing soon after birth. The fecal sodium content was strikingly high (109 mmol/L [normal range, 27–35 mmol/L]) and the osmotic gap was decreased (15 mOsm/kg), consistent with the findings of congenital sodium diarrhea. We examined the mitochondrial respiratory chain function by blue native polyacrylamide gel electrophoresis (BN-PAGE) in-gel enzyme staining, BN-PAGE western blotting, respiratory chain enzyme activity assay, and immunohistochemistry. Liver respiratory chain complex (Co) I activity was undetectable, while other respiratory chain complex activities were increased (Co II, 138%; Co III, 153%; Co IV, 126% versus respective control activities). Liver BN-PAGE in-gel enzyme staining and western blotting showed an extremely weak complex I band, while immunohistochemistry showed extremely weak staining for the 30-kDa subunit of complex I, but normal staining for the 70-kDa subunit of complex II. The patient was, therefore, diagnosed with complex I deficiency. The overall complex I activity of the jejunum was substantially decreased (63% of the control activity). The immunohistochemistry displayed apparently decreased staining of the 30-kDa complex I subunit, together with a slightly enhanced staining of the 70-kDa complex II subunit in intestinal epithelial cells. These data imply that intestinal epithelial cells are also complex I-deficient in this patient. Complex I deficiency is a novel cause of secretory diarrhea and may act via disrupting the supply of adenosine triphosphate (ATP) needed for the maintenance of ion gradients across membranes.     

Living-donor liver transplantation for carbamoyl phosphate synthetase 1 deficiency

CPS1 is a mitochondrial matrix enzyme that catalyzes the first committed step of the urea cycle, the primary system for removing nitrogen produced by protein metabolism using N-acetylglutamate. Patients with CPS1 deficiency have severe hyperammonemia that results in serious neurologic sequelae and sometimes death. LT has been indicated for neonatal-onset CPS1 deficiency. This study retrospectively reviewed five children with a diagnosis of CPS1 deficiency who underwent LDLT from heterozygous donors. Between November 2005 and May 2010, 124 children underwent LDLT with an overall patient and graft survival of 91.0%. Five patients were indicated for LDLT because of CPS1 deficiency. All recipients achieved resolution of their metabolic derangement, without donor complication, with a normal feeding regimen without medication for their original metabolic liver disease. LDLT, even from heterozygous donors, appears to be a feasible option, associated with a better quality of life for treating patients with CPS1 deficiency. Long-term observation may therefore be necessary to collect sufficient data to confirm the efficacy of this treatment modality.     

线粒体基因13513G>A突变导致呼吸链酶复合物I缺陷Leigh综合征

Leigh综合征是由于线粒体呼吸链能量代谢障碍所导致的遗传性疾病,呼吸链酶复合物I缺陷是导致Leigh综合征的常见原因之一。该研究通过线粒体基因13513G>A突变分析首次确诊了1例中国人Leigh综合征患者。患儿为第一胎,12岁时出现抽搐,13岁时先后出现双眼视力下降,13岁来院就诊左眼颞侧视野缺损,痉挛步态,血液乳酸、丙酮酸增高,腓肠肌活检肌纤维内脂滴轻度增多;心电图检查显示不完全右束支传导阻滞;脑MRI显示双侧基底节对称性损害,符合Leigh综合征诊断,合并继发性癫癎。经基因分析证实患者存在线粒体基因13513G>A突变,导致线粒体呼吸链酶复合物I活性下降。治疗以多种维生素为主,补充左旋肉碱、辅酶Q10,同时给予卡马西平、苯巴比妥、丙戊酸等抗癫癎治疗。现在患儿16岁,休学,智力无明显倒退,体力、体重显著减退。Leigh综合征病因复杂,临床表现多种多样,该患儿以抽搐起病,合并视力减退,经基因分析明确了病因,有助于相关家庭的遗传咨询 。［中国当代儿科杂志,2009,11（5）：333-336］     

Progressive cardiac failure following orthotopic liver transplantation for type IV glycogenosis

Orthotopic liver transplantation (OLT) has been proposed to treat patients with type IV glycogenosis because of early progressive cirrhosis. Reports have shown absence of disease progression in other organs after OLT and even regression of cardiac amylopectin infiltration in one case. We describe a 15-month-old child in whom a liver transplant was performed for type IV glycogenosis. There were no clinical signs of extrahepatic disease before OLT. Nine months later, the patient developed progressive cardiac insufficiency and died from cardiac failure. Because of massive amylopectin deposits, decreased myofibrils in cardiac cells, and exclusion of other causes of cardiac failure, death was attributed to amylopectinosis. Our observation contrasts with the Pittsburgh experience and suggests that cardiac amylopectionosis may progress after OLT.     

Isolated biotin-resistant 3-methylcrotonyl-CoA carboxylase deficiency: Long-term outcome in a case with neonatal onset

A patient with early-onset 3-methylcrotonyl coenzyme A carboxylase (MCC) deficiency showing a severe clinical course is described. Abnormal eye and head movements suggestive of seizures were noticed soon after birth. Tonic convulsions at the age of 10 weeks led to admission. Urinary organic acid analysis using gas chromatography-mass spectrometry at 3 months of age revealed elevated concentrations of 3-hydroxyisovaleric acid (3HIVA) and 3-methylcrotonylglycine but normal levels of lactate, 3-hydroxypropionate and methylcitrate suggesting isolated MCC deficiency. This was confirmed by enzyme assays in lymphocytes and cultured skin fibroblasts: MCC activity was virtually undetectable whereas activities of propionyl-CoA and pyruvate carboxylases were within the normal range. A low protein (0.8–1.5 g/kg/day) diet supplemented with a leucine-free amino acid mixture resulted in a marked decrease of 3HIVA excretion.l-Carnitine and biotin administration had no effect on the clinical condition or metabolite exretion. Supplementation with glycine resulted in only a temporary fall of 3HIVA excretion and was therefore discontinued.l-Carnitine therapy was reintroduced later because of secondary carnitine deficiency. Compliance with treatment was poor until the age of 27 months resulting in a severe episode with seizures and coma. The general clinical condition of the patient was always good but his psychomotor development was delayed and seizures were not continuously under good control due to poor therapy compliance. The boy is now 10.5 years old and attending a school for children with learning handicaps.     

Risk of hepatocellular carcinoma in liver mitochondrial respiratory chain disorders

Mitochondrial respiratory chain disorders (MRCD) are a large group of disorders that can affect any organ besides muscles or the central nervous system. We report two children who presented with neonatal cholestasis and progressive cirrhosis, who subsequently developed hepatocellular carcinoma (HCC). This suggests a particular risk of degeneration in these patients and the importance of a regular screening for secondary liver cancer. Suggestion of HCC should lead to early liver transplantation, which was successful without tumor recurrence in the two patients.     

Case of an infant with hepatic cirrhosis caused by mitochondrial respiratory chain disorder

The patient had hepatomegaly with liver dysfunction at the age of 1 month. Magnetic resonance imaging performed at the age of 1 year showed multiple nodules of varying size in his liver. We were able to examine the mitochondrial respiratory chain function in the liver biopsy samples because all other differential diagnoses for hepatic cirrhosis had been ruled out. Complex I and IV activities were below the normal level (<30%) of the citrate synthase (CS) ratio. Liver blue native polyacrylamide gel electrophoresis showed an extremely weak complex I and IV band. Liver respiratory chain complexes I and IV were found to be deficient in this patient. The histologic findings were highly suggestive of mitochondrial respiratory chain disorder. Findings of progressive liver cirrhosis changes were observed in magnetic resonance imaging at the age of 5 years. An examination of the mitochondrial respiratory chain function should be performed along with a liver biopsy if mitochondrial respiratory chain disorder is suspected as a possible differential diagnosis of idiopathic hepatitis.     

Atypical phenylketonuria with “dihydrobiopterin synthetase” deficiency: Absence of phosphate-eliminating enzyme activity demonstrated in liver

An assay for the phosphate-eliminating enzyme (PEE) activity in liver was developed which required only 5–10 mg tissue. PEE catalyses the elimination of inorganic triphosphate from dihydroneopterin triphosphate, which is the second and irreversible step in the biosynthesis of tetrahydrobiopterin (BH₄). In the presence of substrate, magnesium, NADPH, and a sepiapterin reductase fraction from human liver, PEE catalysed the formation of BH₄ which was measured by HPLC and electrochemical detection. In adult human liver, a PEE activity of 1.02±0.134 U/mg protein (mean ±1 SD; n=5) was observed. In liver needle biopsy material from five patients with defective biopterin biosynthesis, no PEE activity was found (less than 2% and 6% of the control values, respectively). The presence of an endogenous inhibitor was excluded. In a patient who died without definite diagnosis and in a patient with -thalassaemia liver PEE activity was increased. Sepiapterin reductase activity was present in all cases. Results indicate that in dihydrobiopterin synthetase deficiency, the most frequent of the rare BH₄-deficient variants of hyperphenylalaninaemia, the molecular defect consists in a defect of PEE.Abbreviations PEE Phosphate eliminating enzyme - DHBS Dihydrobiopterin synthetase - HPLC High pressure liquid chromatography - BH₄ tetrahydrobiopterin     

线粒体MT-TE基因突变致可逆性婴幼儿呼吸链缺乏症1例并文献复习

目的探讨线粒体MT-TE基因突变致可逆性婴幼儿呼吸链缺乏症的临床表现及基因突变特点。方法回顾分析1例确诊为可逆性婴幼儿呼吸链缺乏症患儿的临床资料,并复习相关文献。结果男性患儿,2个月23天,入院时消瘦,呼吸急促,双肺可闻及痰鸣音及喘鸣音;肌力IV级,肌张力减弱。有一胞姐生后不久因重症肺炎去世。入院时肌酸激酶同工酶123 U/L,肌酸激酶890 U/L;血乳酸8.9 mmol/L;病原学检查均为阴性。头颅MRI无异常。入院后患儿持续高乳酸血症、肌酶异常升高,伴呼吸困难,放弃治疗后死亡。基因检查示线粒体MT-TE基因存在14674TC突变,来源于母亲。国外文献报道线粒体MT-TE 14674TC突变患儿早期临床表现与进展型线粒体病类似,呼吸肌无力、喂养困难,运动发育里程碑延迟,肌酶及乳酸升高。予补充能量,维持内环境稳定等治疗,约1岁左右逐渐好转。结论线粒体MT-TE基因突变致可逆性婴幼儿呼吸链缺乏症早期表现与进展型线粒体病类似,积极治疗预后良好。早期进行基因检测可明确预后,增强治疗的信心。     

Anaesthesia for liver transplantation in two infants with an organic acidaemia

Liver transplantation is an accepted option of treatment in patients with inborn errors of metabolism limited to or mainly located into hepatocytes who have not responded well to medical treatment. Recurrent metabolic failure and neurological impairment might be an indication for early transplantation in patients with organic acidaemias. We discuss the anaesthetic management and metabolic implications of acidaemia in the first two cases of successfully treated propionic and methylmalonic acidaemia in Italy. A nine and 12 month follow up did not show any further metabolic failure after the procedure, indicating that early liver transplantation improves the quality of life of these patients.     

Glycogen storage disease type I: indications for liver and/or kidney transplantation

Even though significant progress has been achieved in the management of patients with glycogen storage disease type I, hepatic (mainly adenomas) and renal (proteinuria, renal failure) complications may still develop. Orthotopic liver transplantation has been reported in less than 20 patients, and, in most cases, its indications were multiple hepatic adenomas, sometimes combined with poor metabolic control and/or growth retardation. Even though short-term outcome seems to be favourable, long-term complications have been reported in several cases. Thus it appears that improved metabolic control has to be attempted before performing liver transplantation in such patients. As for renal transplantation, it has been performed in patients with terminal renal failure. It is hoped that improving longterm metabolic control will prevent renal involvement from evolving to terminal renal failure. Finally, combined liver and kidney transplantation may be indicated in a few patients.Conclusion: organ (liver/kidney) transplantation in glycogen storage disease type I may be advantageous when long-term metabolic control has been attempted. Nevertheless, post-transplantat longterm complications may still develop. Published online: 19 July 2002     

Successful living domino liver transplantation in a child with protein C deficiency

PC is produced in the liver and inhibits blood coagulation by catalyzing active factors V and VIII. PC deficiency causes abnormal blood clotting that is difficult to regulate by anticoagulative treatments. Four reports of PC deficiency treated with LTx have been published; however, no report of DLT as a therapy for PC deficiency is available. We describe a case of a 23‐month‐old girl who received DLT for compound heterozygous PC deficiency. Her PC activity was below 5%. She developed intracranial lesion and frequent refractory purpura fulminans. Both her parents had heterozygous mutations of PC genes and were excluded as living donors. Furthermore, she was a low priority on the waiting list of deceased‐donor transplantation. We performed living DLT using the liver from a patient with MSUD. Activated PC concentrate safely supported the perioperative period. After DLT, she maintained normal PC activities and BCAA levels. This is the first case of PC deficiency successfully treated by living DLT with MSUD. We propose that DLT using liver from patients with MSUD is a treatment option for PC deficiency.     

Disorders of the mitochondrial respiratory chain: clinical manifestations and diagnostic approach

The clinical identification of patients with defects in the mitochondrial respiratory chain is almost impossible. We describe screening tests that should be performed in order to select those patients in whom a skeletal muscle biopsy should be carried out for more specific biochemical assays. The importance of performing in vivo function tests is stressed. The biochemical diagnosis in disorders of the respiratory chain is presented and the application of immunological methods discussed.Abbreviations ATP adenosine triphosphate - CoA coenzyme A - DCPIP 2,6-dichlorophenol indophenol - KCN potassium cyanide - NAD⁺ nicotinamide adenine dinucleotide (oxidized) - NADH nicotinamide adenine dinucleotide (reduced) - PMS phenazine methosulfate     

Safe and unsafe duration of fasting for children with MCAD deficiency

Objective To study the safe and unsafe duration of fasting in children with medium chain acyl-Coenzyme A dehydrogenase (MCAD) deficiency, the literature and the database on Dutch MCAD-deficient patients were searched for data on fasting studies in patients with MCAD deficiency.Materials and methods These data were extended with information on fasting studies performed on our patients with MCAD deficiency known in the Beatrix Children’s Hospital, UMC Groningen, The Netherlands. The data reflect considerable inter-individual variation and overlap between safe and unsafe duration of fasting.Results In six out of 35 fasting tests, symptoms were reported before hypoglycaemia was observed. Until 1 year of age, the median safe and unsafe duration of fasting was 12 hours (n=7, range 8–19 hours) and 18 hours (n=5, range 15–20 hours), respectively. After the first year of life, the median safe and unsafe duration of fasting was 18 hours (n=17, range 10–24 hours) and 20 hours (n=9, range 13–32 hours), respectively.Conclusion Therefore, to conclude, we recommend a maximum duration of fasting in children with MCAD deficiency of 8 hours between 6 months and 1 year of age, 10 hours in the second year of life and 12 hours thereafter. From this study, no conclusions can be drawn on the duration of fasting during situations of intercurrent illness, especially with fever.     

Allogeneic hematopoietic stem cell and liver transplantation in a young girl with dedicator of cytokinesis 8 protein deficiency

DOCK8 deficiency is a rare inherited combined immunodeficiency, caused by mutations in the DOCK8 gene. We describe a case with DOCK8 deficiency associated with severe CLD in whom orthotopic LT was performed successfully after allogeneic HSCT. A 5 year‐old girl with DOCK8 deficiency presented with mild direct hyperbilirubinemia and abnormal GGT level and without a previous history of jaundice. She had severe growth retardation, hepatosplenomegaly and generalized eczema. Progressive worsening of CLD was observed within 4 months. Investigations for etiology of liver disease were negative. Liver biopsy showed bridging necrosis, cholestasis and, cirrhosis. Recurrent immune hemolytic crisis and several viral infections developed in follow‐up. She underwent whole cadaveric LT for end‐stage liver disease (ESLD) 1 year after allogenic HSCT from a full matched related donor. The postoperative course was uneventful. The patient is alive with normal liver function and moderate skin graft versus host disease for 36 months after LT. In conclusion DOCK8 deficiency can be associated with severe CLD. Successful LT following HSCT is possible in patients with ESLD in DOCK8 deficiency. The timing of LT is challenging in patients requiring both HSCT and LT since conditioning regimens for HSCT can be highly hepatotoxic and the patients with suboptimal liver function can become decompensated during HSCT.     

CPAP by helmet for treatment of acute respiratory failure after pediatric liver transplantation

ARF after pediatric liver transplantation accounts for high rate of morbidity and mortality associated with this procedure. The role of CPAP in postoperative period is still unknown. The aim of the study was to describe current practice and risk factors associated with the application of helmet CPAP. In this retrospective observational cohort study, 119 recipients were divided into two groups based on indication to CPAP after extubation. Perioperative variables were studied, and determinants of CPAP application were analyzed in a multivariate logistic model. Sixty patients (60/114) developed ARF and were included in the CPAP group. No differences were found between the two groups for primary disease, graft type, and blood product transfused. At multivariate analysis, weight <11 kg (OR = 2.9; 95% CI = 1.1‐7.3; P = .026), PaO₂/FiO₂ <380 before extubation (OR = 5.4; 95% CI = 2.1‐13.6; P < .001), need of vasopressors (OR = 2.6; 95% CI = 1.1‐6.4; P = .038), and positive fluid balance >148 mL/kg (OR = 4.0; 95% CI = 1.6‐10.1; P = .004) were the main determinants of CPAP application. In the CPAP group, five patients (8.4%) needed reintubation. Pediatric liver recipients with lower weight, higher need of inotropes/vasopressors, higher positive fluid balance after surgery, and lower PaO₂/FiO₂ before extubation were at higher odds of developing ARF needing CPAP application.     

Living donor liver transplantation from an asymptomatic mother who was a carrier for ornithine transcarbamylase deficiency

Liver transplantation (LT) has been adopted as a radical treatment for ornithine transcarbamylase deficiency (OTCD), yielding favorable outcomes. Despite the fact that it is an inheritable disease, a blood relative who is heterozygous for the disorder must sometimes be used as a liver donor for living donor LT. There is ongoing discussion regarding the use of heterozygous donors, however, to our knowledge, no cases where donation was determined based on the Ornithine transcarbamylase (OTC) activity before LT have been reported. Between May 2001 and April 2011, 17 patients were indicated for living donor LT because of OTCD at our facility. There were three cases with heterozygous donor candidate (17.6%). All heterozygous candidates underwent a liver biopsy to measure their OTC activity before LT and made efforts to secure the safety of the both donor and recipient. Two of 3 candidates had headaches sometimes, and their activity was less than 40%, and thus they were not employed as the donor. One candidate with 104.4% activity was employed, yielding favorable outcomes. Our current experience supported the effectiveness of our donation criteria, however it is necessary to collect sufficient data on a large number of patients to confirm the safety of the procedure.